Paper: Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
A retrospective analysis of over 400 patients treated at 4 large academic medical centers compared outcomes of AML patents treated with CPX-351 vs HMA-Ven. Although there was a survival benefit seen with CPX-351, multivariable analysis of patients aged 60-75 who did not receive a transplant did not show an OS benefit. Additionally, patients who received a transplant had similar survival in both groups. I think this study urges us to continue to consider induction chemo and consolidation transplant in eligible patients and limit HMA-VEN for transplant/induction chemo ineligible, and to consider transplant after HMA / VEN if a patients PS improves.
